For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their ...

These findings support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with "good-risk" DCIS who opt to skip RT. Read on!

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio of ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio ...

Kwality Pharmaceuticals rose 1.95% to Rs 897 after the company announced that it has successfully obtained product approval for its Tamoxifen Tablet from the South African Health Products Regulatory ...

The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer ...